| 摘要 |
The present invention provides methods for the identification of agents, e.g., therapeutic agents, that inhibit Fatty Acid Transport 5 (FATP5) activity, and methods of treating diseases or conditions associated with FATP5 function, e.g., obesity, insulin resistance, type 2 diabetes, dyslipidemia, fatty liver disease, and cardiovascular disease. Further aspects of the invention provide a transgenic FATP5 non-human knockout mammal, e.g., mouse, useful for elucidating the function of FATP5 in intact animals whose genomes comprise a wild-type FATP5 gene.
|
